TY - JOUR
T1 - New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide
AU - van Boxtel, W.
AU - Bulten, B. F.
AU - Mavinkurve-Groothuis, A. M. C.
AU - Bellersen, L.
AU - Mandigers, C. M. P. W.
AU - Joosten, L. A. B.
AU - Kapusta, L.
AU - de Geus-Oei, L. F.
AU - van Laarhoven, H. W. M.
PY - 2015
Y1 - 2015
N2 - Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = -0.564, p ≤ 0.01). The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP
AB - Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = -0.564, p ≤ 0.01). The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP
U2 - https://doi.org/10.3109/1354750X.2015.1040839
DO - https://doi.org/10.3109/1354750X.2015.1040839
M3 - Article
C2 - 25980453
SN - 1354-750X
VL - 20
SP - 143
EP - 148
JO - Biomarkers
JF - Biomarkers
IS - 2
ER -